FORM 4

Check this box if no longer subject to

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

washington, b.c. 20045

CTATEMENIT	\sim r	CHANCEC	INI DE	NICEICIAI	OWNEDCHID
SIAIEWENI	OF	CHANGES		NEFICIAL	OWNERSHIP

OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5

OMB APPROVAL

Section 16. Form 4 or Form 5
obligations may continue. See
Instruction 1(b).
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* ISAACS STEPHEN T				2. Issuer Name and Ticker or Trading Symbol ADURO BIOTECH, INC. [ADRO]							Relationship of Reporting Person(s) to Issuer Check all applicable) X Director 10% Owner						
(Last) (First) (Middle) C/O ADURO BIOTECH, INC. 626 BANCROFT WAY, 3C			3. Date of Earliest Transaction (Month/Day/Year) 06/10/2016							X Officer (give title Other (specify below) President and CEO							
(Street) BERKEI	LEY C.	A	94710		4. 11	4. If Amendment, Date of Original Filed (Month/Day/Year)				Lin	e) X Form f Form f	dual or Joint/Group Filing (Check Applicable Form filed by One Reporting Person Form filed by More than One Reporting Person					
(City)	(S	tate)	(Zip)														
		Tab	le I - Non-	-Deriva	ative	e Se	curities	s Ac	quired, Di	sposed o	of, or Be	neficia	ly Owned	l .			
1. Title of Security (Instr. 3) 2. Transa Date (Month/D			Execution Date,		Code (Ins				Benefici	es ally Following	Form: D	rm: Direct or Indirect (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)				
						Code V	Amount	(A) or (D)	Price	Transact (Instr. 3	on(s)		"	(11150.4)			
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																	
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	Date Execution D	Date, Transaction Code (Instr.					6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficiall Owned Following Reported Transactio (Instr. 4)	ly Di or	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Co	ode	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares					
Employee Stock Option (right to buy)	\$11.99	06/10/2016			A		70,700		(1)	06/09/2026	Common Stock	70,700	\$0.00	70,700)	D	

Explanation of Responses:

1. The shares subject to the Option vest in 48 equal monthly installments from the vesting commencement date of June 10, 2016

Remarks:

/s/ Jennifer Lew, Attorney-in-

Fact

** Signature of Reporting Person

Date

06/10/2016

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.